In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11. The findings of the ...

A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that treatment with dupilumab significantly restores skin barrier function and ...

Robust real-world data on the effectiveness of biologic therapies in children with severe asthma remain limited, particularly ...

Providers from an asthma primary care program found telemedicine to be effective in both caring for children with asthma and addressing unmet social needs that may exacerbate their asthma outcomes.

Sold under the name Dupixent, dupilumab is a biologic that inhibits interleukin (IL)-4 and IL-13, which are key drivers of the type 2 inflammation that plays a major role in asthma, chronic ...

Use of single maintenance and reliever therapy (SMART) for moderate-to-severe asthma saved money by improving outcomes, according to a meta-analysis. While SMART is recommended by guidelines, ...

Please provide your email address to receive an email when new articles are posted on . Rademikibart led to better lung function and asthma control in adults with moderate to severe persistent asthma ...

Asthma is a major noncommunicable disease, affecting both children and adults, and is the most common chronic disease among children, as per World Health Organization (WHO). The condition affected an ...

There’s no cure for childhood asthma, and the condition won’t resolve as a child ages. However, treatments such as inhalers and oral medications can help keep the symptoms under control. Share on ...

HONOLULU -- Although single maintenance and reliever therapy (SMART, or MART) marks a new chapter in asthma treatment, its advocates acknowledged practical limitations during a debate at the CHEST ...

Despite a wealth of available treatments to control the symptoms of chronic asthma, the lung disease has no cure. The discovery of an unexpected cause of asthma could change that. A glitch in the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved dupilumab as an add-on maintenance treatment for children aged 6 to 11 years with moderate ...